Compare Ascendis Pharma A/S (ASND) vs FedEx Corporation (FDX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs FedEx Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while FedEx Corporation trades at $314.69 (market cap $75.09B). The key difference: FedEx Corporation is far larger — about 4.2× Ascendis Pharma A/S's market cap, and FedEx Corporation pays a 1.55% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | FDX | |
|---|---|---|
Market Cap | $17.74B | $75.09B |
Sector | Health | Industrials |
52-Week High | $277.18 | $338.75 |
52-Week Low | $163.32 | $174.81 |
Enterprise Value | $18.11B | $104.72B |
Dividend Yield | — | 1.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
FedEx (FDX) trades at $314.69, up 1.24% on the day, with a bearish technical signal from moving averages but oversold RSI levels. Recent earnings have consistently beaten estimates, with Q1 2026 EPS of $6.31 exceeding expectations. The company is executing strategic moves, including the sale of its supply chain unit to CMA CGM for $1.4 billion and a $4.15 billion debt tender offer to reduce leverage. Fundamentals show stable revenue near $88 billion and a net income margin of 4.68%, though operating cash flow declined to $7.04 billion in 2025.
The outlook is mixed; analyst consensus is bullish with a $365.73 price target, but margin recovery remains uncertain amid competitive pressures from Amazon Logistics. Risks include soft shipping demand and ongoing cost-cutting needs. The stock offers value with a P/E of 16.97, but investors should monitor execution of efficiency initiatives and freight segment performance post-spinoff.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →
